Research programme: infectious disease vaccines - iBio

Drug Profile

Research programme: infectious disease vaccines - iBio

Alternative Names: Anthrax vaccine - iBio; Anthrax-plague combination vaccine - iBio; Cancer vaccine - iBio; HPV vaccine - iBio; Influenza A virus H7N9 vaccine - iBio; Malaria vaccine - iBio; Plague vaccine - iBio

Latest Information Update: 28 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator INB:Biotechnologies
  • Developer iBio Inc
  • Class Anthrax vaccines; Cancer vaccines; Influenza A virus H7N9 vaccines; Papillomavirus vaccines; Parasitic vaccines; Plague vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Bacterial infections; Parasitic infections; Viral infections

Highest Development Phases

  • Preclinical Cancer
  • No development reported Anthrax; Human papillomavirus infections; Influenza A virus H7N9 subtype; Plague

Most Recent Events

  • 18 Oct 2016 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top